Crosstree Announces Sale of SAO Buy-Side Division to 7Sage Partners

Strategic move sharpens Crosstree's focus on life-sciences sell-side advisory while enabling its buy-side team to pursue broader healthcare expansion under new leadership

TAMPA, FLORIDA (July 28, 2026) -

Crosstree Capital Partners, a life-sciences focused sell-side advisory firm, today announced the sale of its Strategic Advisory & Origination (SAO) buy-side division to a newly formed, independent firm, 7Sage Partners LLC. The new firm will be led by Gordon Ryerson, formerly Managing Director at Crosstree, and Michael Levin, formerly Director at Crosstree, who will continue to lead the same team currently servicing the division's existing clients.

The SAO team has expanded its buy-side work into broader healthcare and adjacent sectors in recent years, building engagements beyond Crosstree's core life-sciences sell-side focus. Establishing the buy-side practice as its own entity allows that expansion to continue and scale, while sharpening Crosstree's position and market identity as a dedicated leader in life-sciences sell-side advisory.

"This transition reflects the natural evolution of a team that has outgrown a single practice area. We're proud of what the SAO group has built and formalizing it as its own firm lets that growth continue on its own trajectory while Crosstree stays focused on what we do best."said Shane Senior, Managing Director and Co-Founder at Crosstree.

Current client engagements are unaffected by the transition. The same team, materials, and working relationships carry forward without interruption, and Crosstree and 7Sage will continue to work in close partnership going forward. Clients will retain continuity of team, service, and points of contact throughout.

"We're grateful for our years at Crosstree and for the partnership that continues today. 7Sage lets us bring the same rigor and relationships our clients already know to a broader healthcare mandate."said Gordon Ryerson, Co-Founder of 7Sage Partners.

About Crosstree Crosstree is a distinguished boutique investment banking firm focused exclusively on the needs of middle-market companies within three subsectors of the life sciences and healthcare industries: pharmaceutical services, diagnostics and tools, and digital health. Since 2004, Crosstree has advised on more completed transactions in these collective subsectors than any other investment bank. The firm provides clients a full suite of advisory and capital raising services, including both buy-and sell-side mergers and acquisitions advisory, private capital raising, strategic advisory, and valuations. Crosstree's narrow industry focus provides clients the expertise common of a bulge-bracket investment banking firm to middle-market companies and investors, with unparalleled industry insights, well-established strategic relationships across the globe and superior access to capital markets. From our offices in Tampa, Florida, Crosstree has advised clients throughout North America, Europe, India, China, Latin America, and Australia on transactions ranging from $25 million to more than $1 billion.

All securities transactions are offered by and conducted through Crosstree Capital Securities, LLC, a broker-dealer registered with the SEC, a member of FINRA (www.finra.org) and SIPC (www.sipc.org), and an affiliate of Crosstree Capital Partners, Inc.

About 7Sage Partners

7Sage Partners is a healthcare-focused buy-side advisory firm serving private equity firms and strategic acquirers pursuing inorganic growth across healthcare and life sciences. The firm operates across the full acquisition lifecycle, from investment thesis through deal origination and execution. Learn more at 7SagePartners.com.